1 Patients received 0.2 to 1.25 mg/kg luspatercept subcuta
2 Patients received 0.3 mg/kg of methylphenidate or placeb
3 All 404 consecutively treated
patients received 1 of the following conditioning regime
4 Eighteen eyes (19.1%) of 13
patients received 1.3 +/- 0.6 anti-VEGF injections.
5 Patients received 100 mg oral acalabrutinib twice per da
6 Group B
patients received 1200 mg atezolizumab, administered int
7 For subsequent cycles,
patients received 130 mg/m(2) of intravenous oxaliplatin
8 After thyroid blockade,
patients received (
131)I-omburtamab as a single IP injec
9 Patients received 174 +/- 28 MBq of the radiotracer, whi
10 502 patients received (68)Ga-PSMA-11 and 254
patients received (
18)F-fluciclovine.
11 Patients received 1800 mg of subcutaneous daratumumab co
12 One hundred forty-five
patients received 197 courses of ISA prophylaxis.
13 Methods:
Patients received 2 injections of about 1 GBq (~80 mug)
14 Patients received 2 whole-body (18)F-DCFPyL PET/CT scans
15 Patients received 200 mg of pembrolizumab intravenously
16 Patients received 21-day cycles of gemcitabine (1000 mg/
17 Patients received 21.6 Gy to the preoperative primary tu
18 Eligible
patients received 3-week long cycles of oral selinexor (
19 Patients received 30 courses of maintenance therapy with
20 Patients received 300 mg olaparib in tablet form orally
21 Patients received 40 mg dexamethasone weekly (20 mg for
22 Patients received 400 mg daily of HCQ prior to completio
23 Patients received 400 mg spartalizumab intravenously, on
24 Patients received 480 mg/day for a follow up of 36.1 +/-
25 All
patients received 5 mg of folic acid orally once daily.
26 All
patients received 5-aminolevulinic acid (5-ALA) fluoresc
27 Patients received 5.0 [4.0 to 6.0], 8.5 [8.0 to 10.3] an
28 ed within 30 min to nonprivate residences, 2
patients received 5.55-11.1 GBq (150-299 mCi) of (131)I.
29 Patients received 6 28-day cycles of IV daratumumab, eve
30 All
patients received 6 seconds of HiFU therapy.
31 Patients received 60 mg selinexor orally on days 1 and 3
32 The 55
patients received 62 allografts; 43 (67%) liver-free and
33 Results: In total, 1,502
patients received (
68)Ga-PSMA-11 and 254 patients receiv
34 Enrolled
patients received 7 + 3 induction chemotherapy of contin
35 23 hospitalized severe/critical COVID-19
patients received 700mg leronlimab subcutaneously, repea
36 All
patients received 80 mg of intravenous methylprednisolon
37 Patients received 800 mg of tazemetostat orally twice pe
38 Patients received 800 mg tazemetostat orally twice per d
39 Methods: Fifty-seven LVAD-carrying
patients received 85 whole-body (18)F-FDG PET/CT scans f
40 received percutaneous sclerotherapy and one
patient received a combination of transvenous embolizati
41 A
patient received a deceased-donor small intestinal and c
42 1 patient received a scalp transplant, and 1
patient received a penile transplant.
43 ients received abdominal wall transplants, 1
patient received a scalp transplant, and 1 patient recei
44 All
patients received a 3-drug induction with dexamethasone,
45 8513 (32.8%)
patients received a blood transfusion.
46 The
patients received a bolus of andexanet, followed by a 2-
47 nt upon relapse was diverse: the majority of
patients received a combination of chemotherapy and surg
48 Patients received a conditioning regimen, infusion of do
49 ations were consistent regardless of whether
patients received a device before or after initiation of
50 rcinoids vs 31 reference individuals, and 48
patients received a diagnosis of adenomas vs 50 referenc
51 inoma vs 45 reference individuals (0.02%), 7
patients received a diagnosis of carcinoids vs 31 refere
52 or approximately 75% of clinical events when
patients received a diagnosis of PSC at an age younger t
53 Within 72 hours of extubation, all
patients received a flexible endoscopic evaluation of sw
54 Overall,
patients received a mean (standard deviation [SD]) of 4.
55 Patients received a mean of 27.56 injections in the supe
56 In the intervention group,
patients received a median (interquartile range) of 27.0
57 Patients received a median of 16 (range, 1-23) treatment
58 Patients received a median of 3,400 mL (interquartile ra
59 Patients received a median of 4 cycles (range, 2-12 cycl
60 ients were identified; 54.6% of opioid naive
patients received a perioperative opioid prescription.
61 19-1.58]).Conclusions: A total of 20% of IMV
patients received a prescription for opioids after hospi
62 Patients received a single intravenous administration of
63 Eligible
patients received a single intravesical 75 mL dose of na
64 Of 237 eligible patients, 199
patients received a single IVIg course.
65 e infusion (16 mg/kg, day 1 cycle 1), and 75
patients received a split first dose (8 mg/kg, days 1-2
66 All enrolled
patients received a starting dose of 13.5 mg oral pemiga
67 A total of 24
patients received a stem-cell allograft, and 1 death was
68 f two groups: an intervention group in which
patients received a stepped-care intervention (eight ses
69 biomarker results, and 1404 (83.9%) of 1674
patients received a substudy assignment.
70 Patients received a unified prespecified imaging evaluat
71 All
patients received a uniform transplantation conditioning
72 409 of the
patients received a year's worth of follow-up evaluation
73 The 23 control practices (11,706
patients) received a data file but otherwise, continued
74 303 patients received upadacitinib, and 309
patients received abatacept.
75 Two
patients received abdominal wall transplants, 1 patient
76 Upon completion of the blinded phase, all
patients received active treatment in the open-label per
77 Among them, 11 eyes of 11
patients received additional placement of self-retained
78 e survival (DFS) according to whether or not
patients received adjuvant chemotherapy.
79 Patients received adjuvant therapy at physician's discre
80 Fourteen of 16
patients received adjuvant treatments.
81 Each
patient received all four doses and completed the trial.
82 Forty-two
patients received AMG 420 at 0.2-800 mug/d.
83 Twenty
patients received an 'early' second IVIg course (1-2 wee
84 s were lung (46%) and melanoma (19%); 61% of
patients received an anti-PD-1 agent only.
85 ach year, but no more than 40.4% of diabetic
patients received an examination in any given year.
86 Ninety-four eyes of 66
patients received an FAc implant.
87 In a 1-year randomized controlled trial, 60
patients received an immediately placed implant and prov
88 All the
patients received an implantable cardiac monitoring devi
89 All
patients received an implantable loop recorder.
90 In phase 1,
patients received an intravenous infusion of melflufen a
91 Most
patients received an opioid prescription in the first mo
92 Four
patients received anti-programmed cell death protein-1 (
93 Overall, 77
patients received antibiotic prophylaxis for an average
94 The median number of days that
patients received antibiotics decreased in the teleID gr
95 5% confidence interval [CI], 10.6%-11.3%) of
patients received antibiotics.
96 Regardless of POCT-use, most influenza
patients received antivirals (>80%) and antibiotics (>70
97 Patients received approximately 111 MBq (3 mCi) of (89)Z
98 A total of 36 randomized
patients received ASP4345 (3, 15, 50, and 150 mg; n = 9
99 Pacemaker-dependent
patients received asynchronous pacing.
100 ollow-up of 6.8 (2.5-11.4) years, 78 (47.3%)
patients received at least 1 appropriate ICD therapy.
101 Sixty
patients received at least 1 dose of either study agent;
102 As of 2 July 2018, 71
patients received at least 1 dose of ruxolitinib.
103 87 (97%) of 90
patients received at least one dose of atezolizumab at 1
104 omide, bortezomib, and dexamethasone and 270
patients received at least one dose of bortezomib and de
105 All
patients received at least one dose of cabozantinib.
106 re of CAR(+) T cells (liso-cel), of whom 269
patients received at least one dose of liso-cel.
107 278
patients received at least one dose of pomalidomide, bor
108 All enrolled
patients received at least one dose of study treatment a
109 7, and Nov 26, 2018, 71 (96%) of 74 enrolled
patients received at least one dose of UGN-101.
110 Most
patients received AT supplementation (87%).
111 In group A, all
patients received atezolizumab (1200 mg) and bevacizumab
112 Patients received atezolizumab 840 mg or matching placeb
113 All
patients received baseline preoperative and follow-up me
114 Patients received bilateral dbPET and wbPET following ad
115 In cohort 2, 22
patients received BL-8040 and pembrolizumab with chemoth
116 mutation carriers, approximately half of the
patients received breast-conserving therapy.
117 Patients received brentuximab vedotin at 1.8 mg/kg (dose
118 Patients received cabozantinib (adults 60 mg, children [
119 Patients received cabozantinib 60 mg orally once daily i
120 5064 (39.5%)
patients received CAPOX and 7771 (60.5%) received FOLFOX
121 Control
patients received care as usual.
122 1477
patients received care in either the AH-HaH VOU or VACU
123 Of these, 1293 (88%)
patients received care in the VOU only, with 40 (3%) req
124 Forty-one
patients received CD30.CAR-Ts.
125 A total of 56.0% of
patients received ceftriaxone with metronidazole (hospit
126 121
patients received cementless THA through a minimally-inv
127 Most
patients received checkpoint inhibition for the treatmen
128 The majority of
patients received chronic and serial anti-VEGF injection
129 Patients received coadministered intravenous tafasitamab
130 Thus, the
patient received conservative care and was started on di
131 All
patients received continuous dabrafenib and trametinib d
132 postoperative electrical stimulation and 454
patients received control or sham stimulation.
133 Patients received crossover treatment with either half-d
134 Patients received CYC (n=161) or RTX (n=64) for remissio
135 th cancer were receiving therapy, and 45% of
patients received cytotoxic or immunosuppressive treatme
136 Patients received dabrafenib 150 mg twice per day and tr
137 Patients received decitabine 20 mg/m(2) intravenously fo
138 Between 38.5% and 54.7% of
patients received devices from the manufacturers that ha
139 All
patients received difluprednate with the addition of a t
140 Overall 19.8% (1039/5240) of
patients received early NSAIDs.
141 logeneic donor.METHODSIn this phase I trial,
patients received either 1.5 x 106 MICs per kg BW on day
142 ss, we conducted a randomized trial in which
patients received either low-sodium dialysate (135 mM) o
143 Between October 2017 and July 2019, 19
patients received either nabilone (median dose = 0.75 mg
144 Patients received either venetoclax plus obinutuzumab (o
145 etinal detachment were enrolled, in which 15
patients received encircling while the other 11 segment
146 ced usual care, and a control group in which
patients received enhanced usual care only.
147 A total of 10 114
patients received ERM surgery and met inclusion criteria
148 Patients received escalating doses of EV up to 1.25 mg/k
149 Patients received escalating doses of mavorixafor, up to
150 In all groups,
patients received etoposide 80-100 mg/m(2) on days 1-3 o
151 cation clearance, this study found that most
patients received fewer injections after surgery.
152 ble or probable Alzheimer's disease dementia
patients, received flortaucipir PET scans of 20 min in d
153 y 3 weeks for up to 2 years (35 cycles); all
patients received four cycles of intravenous pemetrexed
154 91
patients received gemogenovatucel-T (n=47) or placebo (n
155 Patients received &
gt;=4 doses (1-1.5 mg/kg/per dose) until
156 Ten
patients received hand transplants and 6 received face t
157 In addition, all the
patients received high-quality supportive care as backgr
158 Thirty-two patients received PDT and 10
patients received HSML.
159 All
patients received hydroxychloroquine (400 mg twice daily
160 Patients received hydroxychloroquine (84%), azithromycin
161 All hospitalized
patients received hydroxychloroquine and azithromycin.
162 In VISTA and VIVID,
patients received IAI 2 mg every 4 weeks, IAI 2 mg every
163 ts received laser therapy, and laser therapy
patients received IAI 2 mg every 8 weeks (after 5 monthl
164 Patients received ifosfamide (2.5 g/m(2) per dose intrav
165 Thirty-one
patients received imipenem/relebactam and 16 colistin+im
166 The remaining
patients received immediate postoperative CRT after near
167 In the first trial,
patients received induction chemotherapy followed by che
168 A total of 87 844
patients received initial anti-VEGF injections for nAMD,
169 Patients received injection with ranibizumab (0.5 mg/0.0
170 All
patients received intensive medical treatment without st
171 Patients received intramuscular 2 mg GX-188E at weeks 1,
172 Of 5581 DPs identified, 4708 (84.4%)
patients received intraoperative drains and early remova
173 In part 2 of SIRIUS,
patients received intravenous daratumumab 16 mg/kg once
174 All
patients received intravenous immunoglobulin, with adjun
175 Patients received intravenous nivolumab 3 mg/kg every 2
176 Patients received intravitreal ranibizumab 0.5 mg inject
177 203 (79%)
patients received invasive mechanical ventilation for a
178 Forty-five
patients received isatuximab (5 [n = 8], 10 [n = 31], or
179 175 (90%)
patients received itraconazole and 19 (10%) received vor
180 Twenty-three
patients received ivosidenib plus azacitidine (median ag
181 Patients received JNJ-8678 (n = 37) or placebo (n = 7).
182 , if rescue treatment criteria were met, IAI
patients received laser therapy, and laser therapy patie
183 cardiovascular and renal dysfunction, older
patients received less organ support.
184 Patients received levosimendan 1 mg daily, 1 mg two time
185 ients that were included in the analysis, 57
patients received liposomal bupivacaine, 55 patients rec
186 Three of the 5 colonized
patients received long-term rifaximin treatment to preve
187 ls was met in all CAR-naive patients, and 22
patients received LV20.19 CAR T cells on protocol.
188 Patients received lymphodepletion followed by CTL019 as
189 Twenty-three
patients received M6620 with carboplatin, with mechanism
190 Patients received maintenance (lenalidomide +/- ixazomib
191 In separate Phase 2 trials, 120
patients received maribavir for cytomegalovirus (CMV) in
192 In the mBCG arm, 23/25 (92.0%)
patients received mBCG, four had nonmuscle invasive blad
193 In total, 175
patients received mechanical ventilation; 44.6% were fem
194 About half of
patients received monotherapy as 2 L chemotherapy for ad
195 Diabetic
patients received more eye examinations than controls in
196 Eyes from ANZ
patients received more injections than eyes from Swiss s
197 In the dose-escalation part, 24
patients received MP0250 as a 3-hour infusion once every
198 Six
patients received multiple courses of miltefosine.
199 Twenty-three patients received saline and 21
patients received n-3 PUFAs.
200 Patients received neoadjuvant SOC chemotherapy (FOLFIRIN
201 Patients received neoadjuvant treatment with intravenous
202 Patients received neoadjuvant treatment with intravenous
203 Patients received nivolumab 1 mg/kg and ipilimumab 3 mg/
204 All
patients received nivolumab alone with subsequent arm al
205 A total of 136
patients received no therapy, 113 received just chemothe
206 transplantation and 4 chemotherapy), 4 (15%)
patients received no treatment, 2 (8%) had unavailable d
207 al measurements were recorded; periodontitis
patients received non-surgical periodontal treatment, an
208 During the study period, 13,540
patients received noninvasive ventilation (25.2%; 95% co
209 Patients received olaparib 300 mg orally twice a day unt
210 Patients received omalizumab for at least 2 months befor
211 Patients received once-daily bezafibrate (400 mg) or pla
212 Twenty-seven SARS-CoV-2 pneumonia
patients received one 400 mg dose of tocilizumab.
213 All 118
patients received one dose of study drug and were includ
214 G) trials were pooled and analysed, in which
patients received one of six CBMPs containing regulatory
215 Patients received optic disc photography every 3 months
216 All
patients received oral cedazuridine/decitabine in subseq
217 Patients received oral doses of enasidenib at 60-300 mg
218 In part B,
patients received oral osimertinib 80 mg and savolitinib
219 Patients received oral vancomycin 125 mg twice daily, st
220 EGFR TKI and were Thr790Met negative; these
patients received osimertinib 80 mg plus savolitinib 300
221 In part D, 42
patients received osimertinib plus savolitinib 300 mg.
222 In part B, 138
patients received osimertinib plus savolitinib 600 mg (n
223 K) data of the OPTILIV trial in which cancer
patients received oxaliplatin, 5-fluorouracil and irinot
224 Forty
patients received PAH-approved drugs with a significant
225 Seventy-two
patients received parsaclisib monotherapy (5-45 mg once
226 Thirty-two
patients received PDT and 10 patients received HSML.
227 Once a
patient received peg-filgrastim, it was administered in
228 ent underwent endoscopic tissue removal, one
patient received percutaneous sclerotherapy and one pati
229 une 16, 2014, and March 31, 2019, 1082 (58%)
patients received personalised reports based on their mo
230 One hundred twenty-two
patients received placebo and 121 Intravenous Abx.
231 15, 50, and 150 mg; n = 9 each dose) and 12
patients received placebo.
232 13-2018, a total of 122 upper eyelids of 117
patients received platinum segment chains (mean weight,
233 All
patients received positive end-expiratory pressure (PEEP
234 A total of 487
patients received postoperative electrical stimulation a
235 All
patients received postoperative laryngoscopies and stand
236 ger proportion of DAA-treated than untreated
patients received potentially curative HCC therapy for r
237 In the intervention arm, 1354
patients received prebiotic or symbiotic preparations, w
238 Only 36.1% of
patients received preincision infusion of vancomycin in
239 nosis was prevalent, and the majority of the
patients received prescription opioid doses below the ri
240 ites and portal vein thrombosis although the
patient received proper anticoagulation therapy.
241 Ten of the 11
patients received prophylactic anticoagulant therapy; ve
242 No
patients received prophylactic cranial radiation; howeve
243 Of 349 MERS patients, 144 (41.3%)
patients received RBV/rIFN (RBV and/or rIFN-alpha2a, rIF
244 A total of 135
patients received RDV, 20 patients had SRI.
245 Patients received recommendations regarding calcium inta
246 Both
patients received reduced intensity conditioning regimen
247 A total of 622
patients received relugolix and 308 received leuprolide.
248 A total of 115 eyes of 90
patients received repeat SLT during the first 18 months
249 All
patients received routine subcutaneous chemical venous t
250 Twenty-three
patients received saline and 21 patients received n-3 PU
251 Periodontitis
patients received scaling and root planing using machine
252 G-AgP
patients received scaling and root planning (SRP), per q
253 Forty-seven
patients received selatogrel 8 mg (n = 24) or 16 mg (n =
254 rsion 6.0 of the protocol; the remaining 127
patients received selinexor 60 mg and were included in a
255 Infected
patients received significantly more saline flushes than
256 Patients received siltuximab infusions of 11 mg/kg every
257 patients received liposomal bupivacaine, 55
patients received simple bupivacaine and 52 received pla
258 he COG A3973 historical cohort, in which all
patients received single SCT and 21.6 Gy without a boost
259 ycles without CNS prophylaxis, and high-risk
patients received six cycles with intrathecal CNS prophy
260 Patients received standard treatment for HFrEF.
261 All
patients received standard-of-care antibiotics.
262 Forty-six
patients received stem cell transplantation (20 autologo
263 disorder of the gastrointestinal tract, the
patient received steroid therapy, only for 2 months.
264 Patients received subcutaneous daratumumab (DARA SC) wee
265 Fewer rural
patients received surgery at a HVH compared to urban pat
266 ents had ocular involvement and 103 of those
patients received systemic treatment for MMP.
267 Monitoring Board on July 27, 2016, after 168
patients received the allocated intervention, based on t
268 One hundred percent and 99% of
patients received the assigned intervention in the PVI-a
269 All
patients received the assigned study treatment, and 34 (
270 All
patients received the augmented Berlin-Frankfurt-Muenste
271 Of these, 10
patients received the first daratumumab dose as a single
272 Patients received the hepatocyte-directed antisense olig
273 Over the study period, surgical
patients received the highest proportion of potent opioi
274 After an interim analysis, 10 additional
patients received the selected (high) dose and of these,
275 1098 (91%) of 1208
patients received their allocated treatment, and most co
276 All 64
patients received their assigned treatment.
277 Although 56
patients received therapy >72 hours with a carbapenem, n
278 Low-risk
patients received three cycles without CNS prophylaxis,
279 endations and compared with Myeloma IX, more
patients received thromboprophylaxis (80.5% vs 22.3%) wi
280 During weeks 28 to 52,
patients received treatment as needed per prespecified c
281 12
patients received treatment for acute myeloid leukaemia-
282 A total of 128 eligible
patients received treatment on protocol.
283 Most incident RRD
patients received treatment within 60 days post-diagnosi
284 All
patients received twice per week carfilzomib at 56 mg/m(
285 Overall, 119
patients received TZP or carbapenems as empirical treatm
286 jection episodes were noted, even though the
patients received up to 1.3 x 1010 donor mononuclear cel
287 Methods: Forty-three NET
patients received up to 4 cycles of (90)Y-DOTATOC at 1.8
288 Patients received up to four cycles of platinum-etoposid
289 All
patients received up to nine 6-week cycles of subcutaneo
290 Patients received up to ten 21-day cycles of docetaxel (
291 A total of 303
patients received upadacitinib, and 309 patients receive
292 ebo patients were crossed over such that all
patients received ustekinumab for 52 weeks.
293 Standard arm
patients received usual care.
294 dian of 18 days (IQR 9-28), 170 (66%) of 257
patients received vasopressors and 79 (31%) received ren
295 In cycle 1, all
patients received vemurafenib and cobimetinib only; atez
296 m was terminated prematurely, and subsequent
patients received vinblastine monotherapy instead.
297 Every
patient received visual acuity testing, SD-OCT and slit
298 34
patients received vorinostat, tamoxifen and pembrolizuma
299 Ten
patients received XOR inhhibitor therapy pretransplant (
300 Ten
patients received XOR inhibitor therapy pretransplant (1